Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
نویسندگان
چکیده
INTRODUCTION Ankylosing spondylitis (AS) is an idiopathic chronic inflammatory disease that has prominent effects on the spine and peripheral joints. In addition, extraarticular manifestations such as enthesitis and acute anterior uveitis may be clinically important. In recent years, the therapy of AS has changed, largely due to the introduction of inhibitors of the proinflammatory cytokine tumor necrosis factor (TNF). Adalimumab, a human monoclonal antibody specifically for TNF, is the most recent of the TNF blocking agents that have been approved for the treatment of active, nonsteroidal antiinflammatory drug (NSAID)-refractory patients with AS. AIMS To evaluate the evidence for the therapeutic value of adalimumab in ankylosing spondylitis. EVIDENCE REVIEW There is clear evidence that adalimumab, administered 40 mg subcutaneously every 2 weeks, substantially improves the signs and symptoms of NSAID-refractory, active AS when compared with placebo treatment. There is ample evidence that adalimumab causes significant improvements in physical health status and overall AS-specific, health-related quality of life and physical functioning, which consequently leads to better work productivity. There is substantial evidence that adalimumab improves spinal and sacroiliac joint inflammation in AS patients. Initial results from clinical trials suggest that there is no increased risk of serious infections or malignancies in adalimumab-treated patients with AS. The most common adverse events were injection-site reactions. Limited economic evidence suggests that adalimumab 40 mg may be cost effective when used according to current valid treatment guidelines. PLACE IN THERAPY Adalimumab is an effective treatment for patients with active AS.
منابع مشابه
Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab.
We present a rare case of splenic tuberculosis in a 42-year old man with long-standing ankylosing spondylitis treated with adalimumab. We review the association between antitumor necrosis factor therapy and splenic tuberculosis. Our case, like many other reported cases, illustrates that the index of suspicion of tuberculosis in patients treated with anti TNF therapies must be high and emphasize...
متن کاملBULLETIN BOARD Latest data on adalimumab therapy for ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis
Results recently presented at the Annual refractory to them over time. Adalimumab Of those who had experienced no response European Congress of Rheumatology in Paris, France, suggests that adalimumab is safe and effective in patients with ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis who are not responding to anti-TNF therapy. In a recent series of studies, adalimumab was...
متن کاملAn Atypical Case of Plasmodium vivax Malaria after Initiating Adalimumab Therapy
We report an unusual case of Plasmodium vivax malaria that occurred in a 22-year-old ankylosing spondylitis patient after initiating adalimumab therapy. P. falciparum malaria was initially included as a possible differential diagnosis due to hyperparasitemia and similar features in the peripheral blood smear. The patient was successfully treated with conventional therapy for P. vivax malaria.
متن کاملCost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
OBJECTIVES This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS). METHODS The analysis was based on pooled data from two Phase III studies of adalimumab in active AS. Patients with an inadequate response to >/=1 NSAID received adalimumab 40 mg every other week (n = 246) or placebo (n = 151) for 24 weeks. A microsi...
متن کامل